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suggesting an involvement of perlecan in myopathies.
In the perlecan morphants, primary intersegmental vessel
sprouts, which develop through angiogenesis, fail to extend and show reduced protrusive activity. Live videomicroscopy conﬁrms the abnormal swimming pattern caused
by the myopathy and anomalous head and trunk vessel
circulation. The phenotype is partially rescued by microinjection of human perlecan or endorepellin. These ﬁndings indicate that perlecan is essential for the integrity of
somitic muscle and developmental angiogenesis and that
endorepellin mediates most of these biological activities.

Introduction
Heparan sulfate proteoglycans (HSPGs) comprise a complex
and heterogeneous family of macromolecules that are preferentially located at the cell surface and basement membrane
(Whitelock and Iozzo, 2005; Knox and Whitelock, 2006; Bishop
et al., 2007). Perlecan, an archetypal HSPG with a large multivalent protein core, regulates basement membrane assembly,
vascular and cartilage development, and tumor growth and
angiogenesis (Mathiak et al., 1997; Iozzo, 1998; Iozzo and San
Antonio, 2001; Hassell et al., 2002). The biology of perlecan
extends far beyond the original notion as an anionic filter. This
complex molecule has a variety of roles: perlecan is a structural
constituent of basement membranes and is a key regulator of
several growth factor signaling pathways and lipid metabolism
(Fuki et al., 2000; Iozzo, 2005; Lindner et al., 2007). Moreover,
although as a parent molecule, perlecan is proangiogenic (Aviezer
et al., 1994; Sharma et al., 1998; Iozzo and San Antonio, 2001),
a C-terminal perlecan fragment named endorepellin has antiCorrespondence to Renato V. Iozzo: iozzo@mail.jci.tju.edu
Abbreviations used in this paper: AChE, acetylcholine esterase; AChR, acetylcholine receptor; DA, dorsal aorta; DIC, differential interference contrast; DLAV,
dorsal longitudinal anastomotic vessel; dpf, days postfertilization; hpf, hours
postfertilization; HSPG, heparan sulfate proteoglycan; ISH, in situ hybridization;
ISV, intersegmental vessel; PCV, posterior cardinal vein; SIV, subintestinal vessel.
The online version of this article contains supplemental material.
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angiogenic activity in tumor xenograft models (Mongiat et al.,
2003; Bix et al., 2004, 2006; Woodall et al., 2008). Proteomic
profiling of endorepellin-targeted action on the endothelium has
recently identified five key proteins involved with endorepellin
angiostatic activity (Zoeller and Iozzo, 2008).
The multiple developmental roles of perlecan are difficult
to dissect in placental animals because disruption of the perlecan gene leads to embryonic lethality (Arikawa-Hirasawa
et al., 1999; Costell et al., 1999). Nearly half of the perlecan-null
mice die at embryonic days 10–12 because of hemorrhage
within the pericardial cavity (Costell et al., 1999). The animals
that survive exhibit severe cephalic and cartilage abnormalities
and die of respiratory failure just after birth (Arikawa-Hirasawa
et al., 1999). The phenotype of perlecan-null animals is quite
complex in so far as a close analysis of all of the embryos that
reach later stages of development show malformations of the
cardiac outflow tract, including transposition of the great vessels
and abnormal coronary artery development (Costell et al., 2002;
González-Iriarte et al., 2003). A viable mutant animal has been
generated in which mice lack perlecan exon 3, which contains
two of the three possible heparan sulfate attachment sites (Rossi
et al., 2003). Interestingly, the animals are viable and fertile but
have small eyes and show degeneration of the lens within 3 wk
of birth (Rossi et al., 2003). Various experimental challenges of
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erlecan’s developmental functions are difﬁcult to dissect in placental animals because perlecan disruption
is embryonic lethal. In contrast to mammals, cardiovascular function is not essential for early zebraﬁsh development because the embryos obtain adequate oxygen by
diffusion. In this study, we use targeted protein depletion
coupled with protein-based rescue experiments to investigate
the involvement of perlecan and its C-terminal domain V/
endorepellin in zebraﬁsh development. The perlecan morphants show a severe myopathy characterized by abnormal
actin ﬁlament orientation and disorganized sarcomeres,

Supplemental Material can be found at:
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these heparan sulfate–deficient mice result in increased stenosis
in injured carotid arteries (Tran et al., 2004) and impaired angiogenesis and tumor growth (Zhou et al., 2004).
In contrast to mammals, intact cardiovascular function is
not essential for early zebrafish development because the embryos obtain adequate oxygen by simple diffusion from the environment. Morpholino-modified antisense knockdown of the
perlecan gene allows the morphant embryos to survive for days
essentially half-way through early larval development (ⵑ7 d
postfertilization [dpf]), thereby permitting, for the first time, a
detailed analysis of the role of perlecan in various systems during early and late embryogenesis.
In this study, we focused on the role of perlecan in zebrafish
muscle and cardiovascular development. The perlecan morphants showed a severe myopathy characterized by abnormal
fiber orientation, reduced amounts of actin filaments, and
disorganized sarcomeres, suggesting a potential role for perlecan in human myopathies. Moreover, primary intersegmental
vessel (ISV) sprouts initiated but did not completely extend and
showed reduced protrusive activity; often the sprouts were very
thin and blunt ended and either failed to anastomose or formed
irregular junctions. Live videomicroscopy confirmed both the
abnormal swimming motion caused by the muscular defects
and the anomalous circulation in the head and trunk vessels.
The morphant phenotype could be partially rescued by microinjection of human perlecan isolated from endothelial cells or
by its C-terminal domain V/endorepellin. Collectively, our findings indicate that perlecan is essential for the development and
integrity of somitic muscle and developmental angiogenesis
and that its C-terminal module endorepellin mediates most of
these biological activities.
382
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Results
Cloning and developmental expression of
zebraﬁsh perlecan

We characterized the zebrafish perlecan sequence by electronic PCR and cloned zebrafish endorepellin by RT-PCR (TPA
BK006379). From a comprehensive database analysis, we conclude
that zebrafish perlecan has an overall structure similar to the mammalian counterpart with an estimated Mr of ⵑ370 kD (Fig. 1 A) and
good conservation of domains II–V (Tables S1 and S2, available at
http://www.jcb.org/cgi/content/full/jcb.200708022/DC1). Notably,
zebrafish perlecan lacked the first 56 amino acid residues and
did not contain the SGD triplets present in the mammalian counterpart where the heparan sulfate chains are attached. However,
there are 14 SG dipeptides dispersed throughout domains III–V
(Table S2), with several of those conforming to the glycosaminoglycan-binding consensus found in other HSPGs (Bishop et al.,
2007; Wang et al., 2007). Initial experiments showed that zebrafish perlecan is indeed an HSPG because it was completely
resistant to chondroitinase ABC but was sensitive to heparitinase
treatment (unpublished data). The exact domain in which the heparan sulfate chains are attached is not yet known. Moreover, nine
Ig repeats were not present in zebrafish perlecan. Analysis of the
available zebrafish database showed that there is one single gene
encoding zebrafish perlecan and that it was localized to chromosome 23 syntenic to human chromosome 1 and mouse chromosome 4, where the mammalian orthologues are located (Fig. 1 B).
Comparative analysis of human, mouse, zebrafish, and Drosophila melanogaster domain V/endorepellin showed a high degree of conservation with ⵑ60% sequence identity and >70%
homology between human and zebrafish endorepellin (Fig. S1 A).
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Figure 1. Analysis of zebraﬁsh perlecan. (A) Schematic of human and zebraﬁsh perlecan protein core. The roman numerals indicate the ﬁve domains.
A key for the various modules is presented at the bottom. Arrows indicate the perlecan MO-DI, MO-DIII, and MO-DV morpholino targeting sites. See Fig. S1
for additional information (available at http://www.jcb.org/cgi/content/full/jcb.200708022/DC1). (B) Zebraﬁsh perlecan is conserved syntenically.
The zebraﬁsh perlecan gene (hspg2) maintains a syntenic relationship with DDOST, PHC2, and SARS of mammalian species. Species and respective
chromosome number are depicted; gene symbols are followed by the gene identiﬁcation numbers from the National Center for Biotechnology Information
Entrez Gene database, and distances between genes are displayed in megabases.
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The BMP-1–sensitive site that would liberate the last globular
domain of endorepellin, LG3, was perfectly conserved among
human, mouse, and zebrafish, further stressing the potential biological significance of this protease-sensitive site (Gonzalez et al.,
2005). Phylogenetic analysis of endorepellin from 13 separate
species (Fig. S1 B) indicates that zebrafish and mammalian
endorepellin evolved from a common ancestor.
To determine the spatiotemporal expression of zebrafish
perlecan, we used whole mount in situ hybridization (ISH) and
immunohistochemistry. ISH using a domain V antisense RNA
probe showed the prominent expression of perlecan at the 20somite stage in the head and somite region (Fig. 2, A and B).
Perlecan was more clearly expressed at 1 dpf in these regions and
was localized along the lateral myotomes (Fig. 2 C) and in the
major axial vessels (Fig. 2 D). At 5 dpf, perlecan was expressed
in the head and intestinal organs, with strong positivity in the
axial vessels, including the dorsal aorta (DA) and the dorsal longitudinal anastomotic vessel (DLAV) as well as in the myoseptae,
the ISVs, and posterior cardinal vein (PCV; Fig. 2, F and G).
Whole mount immunohistochemistry using an affinitypurified rabbit anti–mouse perlecan antibody (Handler et al.,

Downloaded from www.jcb.org on May 22, 2008

Figure 2. Spatiotemporal expression patterns of zebraﬁsh perlecan mRNA and protein. (A–G) Whole mount ISH with a digoxigenin-labeled perlecan
domain V antisense probe for the localization of perlecan mRNA (blue/purple staining). Perlecan mRNA can be detected at the 20-somite stage in regions
of the developing brain (A) and along both sides of the notochord (B, arrows). At 1 dpf, perlecan expression is seen in the head region (C), in the developing somites (C, black arrows), and within the developing axial vasculature (D, arrows). Also note perlecan expression localized within the duct of
Cuvier (C, red arrows). By 5 dpf (F and G [magniﬁed image of the region boxed in F]), perlecan expression signiﬁcantly increases throughout the trunk
musculature (G, arrows), the major trunk/tail vessels including the DLAV, DA, and PCV, and in the developing gastrointestinal tract and future ﬁn regions.
(E) ISH with a digoxigenin-labeled perlecan domain V sense probe. ISH was performed in groups of two to ﬁve samples, and representative images are shown.
(H–N) Whole mount immunohistochemistry with an afﬁnity-puriﬁed anti–mouse perlecan antibody. Perlecan can be detected as early as the 64- and
1,000-cell stage of embryonic development (2 and 3 hpf, respectively) throughout the cell mound (I and J). At 1 dpf, perlecan protein (L and M) is detected
throughout the head (L, arrow), trunk, and tail and is speciﬁcally localized to the developing muscle myoseptae (M, arrows) and the developing vasculature.
By 2 dpf (N), perlecan protein is speciﬁcally detected in the trunk vasculature, including the DLAV (N, black arrows) and axial vessels (N, white arrows).
(H and K) Immunohistochemistry images in which the primary antibody was omitted. Bars, 500 μm.

1997) showed strong positivity at the 64- and 1,000-cell stage
2 and 3 h postfertilization (hpf; Fig. 2, I and J), at a time when
zygotic transcription has not yet commenced, indicating that
perlecan was maternally derived. At 1–2 dpf, perlecan epitopes
were detected in the head region, in the developing eyes, along
the myoseptae, and at the major axial vessels (Fig. 2, L–N),
which is in agreement with the ISH results. The robust early
embryonic expression of zebrafish perlecan indicates that this
gene product is important for early embryogenesis.
Perlecan is essential for zebraﬁsh
embryonic development

To asses the developmental roles of perlecan, we selectively
blocked the translation of perlecan mRNA using morpholino antisense oligonucleotides (MO), a specific translation inhibitor in
zebrafish (Nasevicius and Ekker, 2000). We initially used two
morpholinos of nonoverlapping sequence: one directed against
the translation start site (MO-DI) of perlecan and the other encompassing the splice donor site of the initial exon of domain V/
endorepellin (MO-DV; Fig. 1 A). Embryos at the one- to twocell stage were injected with 2.5–10 ng morpholino, and embryos
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Figure 3. Classiﬁcation and veriﬁcation of the perlecan morphant phenotype. (A) All observed perlecan morphant phenotypes can be classiﬁed according
to the degree of body twisting as presented for MO-DI. Categories include mild (least striking twisted body but noted tail phenotype), moderate (general
twisted body usually accompanied by curly tail up), and severe (signiﬁcant body plan shortening accompanied by twisting of the tail). (B) Mean observed
frequencies of the twisted body classes from MO-DI perlecan morphant embryos (n = 232). Error bars represent ±SEM. (C) Phenotypic overview of perlecan
splice junction–blocking MO-DIII. (D) RT-PCR veriﬁcation of domain III splice junction–blocking morpholino effect. Note the band shift in morpholino-injected
embryos (lane 5) versus uninjected embryos (lane 4), verifying the splice-blocking/intron retaining effect of MO-DIII. Lane 1, DNA ladder; lane 2, domain III
PCR from zebraﬁsh cDNA template; lane 3, domain III PCR from genomic DNA template; lane 4, domain III PCR from uninjected embryos’ cDNA template;
lane 5, domain III PCR from MO-DIII–injected embryos’ cDNA template. The bottom bands in lanes 4 and 5 represent the ␤-actin control. Template from lanes
4 and 5 were derived from total RNA isolated from 23 embryos. See Fig. 1 A for additional details regarding the targeting positions of the morpholinos.
(E–G) Whole mount immunohistochemistry for veriﬁcation of domain III morpholino-based knockdown of perlecan. (E) Control uninjected embryo (2 dpf) shows
perlecan expression throughout the trunk musculature and vasculature. (F and G) MO-DIII embryos (2 dpf) show signiﬁcantly reduced perlecan protein levels
in the trunk, with only minimal staining detected in the head and tail. A and E–G are left-side views with dorsal up and anterior to the left. Bars, 500 μm.

from the same matings were injected with an equal volume of phenol red/nuclease-free water mixture as a control. Higher morpholino concentrations (5–10 ng) caused significant lethality, especially
for MO-DV; thus, we used 2.5 ng or less of the morpholinos. Both
morpholinos produced an identical phenotype >90% (n = 358;
P < 0.001; 10 independent experiments) with severe defects in the
384
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cardiovascular and musculoskeletal systems that became visible at
1 dpf (Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200708022/DC1) and became progressively more apparent as
development proceeded (Fig. S2, B–E). At 2 dpf, the morphants
displayed a pronounced curvature of the tail and trunk, which
could be classified as mild, moderate, or severe twisting of the

Published April 21, 2008
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Figure 4. Ultrastructural analysis of perlecan morphant embryos. (A and B) Parasagittal epon sections stained with toluidine blue from 4 dpf control (A) and
MO-DV morphant embryos (B). Note the irregular structure and organization of the morphant’s skeletal muscle and associated abnormal u-shaped myoseptal
boundaries. The DA appears collapsed in the morphant and devoid of blood cells. NC, notochord; DA, dorsal aorta; PCV, posterior cardinal vein. (C–I) A comparison
of morphant and control basement membrane structure. Electron microscopy of the vascular (C–E), epithelial (F and G), and notochord basement membranes (BM;
H and I) suggest that morpholino-based perlecan knockdown does not compromise the integrity of the basement membrane. Bars: (A and B) 25 μm; (C–I) 1 μm.
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body (Fig. 3, A and B). The morphants exhibited either no escape
response or uncoordinated movements in response to tactile stimuli and often swam in a circular fashion (Video 1).
To further corroborate the specificity of the morpholinoinduced perlecan phenotype, we used an additional splicingblocking morpholino-targeting domain III (MO-DIII; Fig. 1 A).
The phenotype evoked by MO-DIII was identical to that evoked
by MO-DI and MO-DV (Fig. 3 C). In five independent experiments (n = 192), MO-DIII injections caused a phenotype in 93 ±
5% of the injected embryos (P < 0.001). To establish that perlecan
knockdown was responsible for the developmental anomalies,
we purified total RNA from pooled control and MO-DIII–treated
embryos (n = 23 for each group) and performed RT-PCR using
two primers flanking the targeted exon of domain III. The predicted unprocessed RNA induced by MO-DIII would yield a
band of ⵑ300 bp, whereas the processed RNA would yield a
band of ⵑ150 bp. As positive controls, we used cDNA (Fig. 3 D,
lane 2) and genomic DNA (Fig. 3 D, lane 3). MO-DIII completely abolished the properly processed perlecan mRNA as
shown by the exclusive presence of the longer transcript of 300 bp
(Fig. 3 D, lane 5) in contrast to the untreated embryos, which
showed only the processed RNA band of 150 bp (Fig. 3 D, lane 4).
In support of the specific perlecan knockdown, whole mount
386
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immunohistochemistry with the antiperlecan antibody showed a
marked suppression of perlecan expression in the morphants
(Fig. 3, F and G) as compared with controls (Fig. 3 E). The effects of the three morpholinos phenocopied each other, providing
evidence that the observed developmental defects were specific
for perlecan knockdown. The observed perlecan morphant’s
phenotype does not appear to be the result of developmental delay because we observed the onset of the heart beat and pigment
development in all embryos. The morphants also exhibited a progressive dilatation of the pericardial sac in >90% of the cases.
The embryos with the most severe phenotype survived 2–3 d,
whereas the milder phenotype survived up to 7–9 dpf, at which
time all of the morphants expired with severe generalized edema
and cardiac failure, as shown by a progressive reduction in ventricular function and contractility.
To further prove the specificity of the observed perlecan
knockdown phenotype, we performed two additional experiments
in which we injected MO-DI and a morpholino targeting the p53
gene. The rationale for these studies is based on a recent report that
morpholinos can nonspecifically activate the p53 gene, causing
off-target phenotypic effects that are not caused by the specific
morpholino used (Robu et al., 2007). In both experiments, the
coinjection of MO-DI and p53 morpholino maintained the MO-DI
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Figure 5. Perlecan morphants display a complex muscular dystrophy phenotype. (A, D, and F) Ultrastructural analysis of control skeletal muscle from a 5-dpf
embryo. Parasagittal (A) and cross sections (D and F) of trunk muscle show typical muscular architecture with alignment of z bands, abundant glycogen (Gly)
and mitochondria (Mi), and typical hexagonal arrays of thick and thin ﬁlaments (D). High magniﬁcation view shows thick ﬁlaments surrounded by six thin
ﬁlaments (circle in F). In contrast, perlecan morphants induced by either translation-blocking (B) or splice-blocking (C, E, and G) morpholinos show disarray of
muscular architecture with loss of ﬁlaments and irregular ﬁlaments traversing the sarcomeres at variable angles (arrows in B and C). Also notice the presence
of areas with reduced thin ﬁlaments (asterisks in E) adjacent to more normal-appearing hexagonal structures (E). The sarcoplasmic reticulum (SR) appears to
be normal (E). High magniﬁcation of the area labeled by the asterisk in E shows abnormal arrangement of thin and thick ﬁlaments (circle in G). Bars, 1 μm.
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phenotype (Fig. S2 F), further confirming the specificity of MO-DI
phenotypic effects. Any observed defects in head, brain, or eye
development are likely nonspecific side effects of MO-DI morpholino because coknockdown with p53-MO did not maintain these
phenotypic abnormalities. Additionally, a morpholino standard
control oligonucleotide did not induce any phenotype (Fig. S2 F).
Perlecan is not required for the formation
of most basement membranes

Longitudinal sections of the trunk of 4-dpf control zebrafish
showed a well-formed DA filled with red cells and a properly
developed PCV (Fig. 4 A). In contrast, in the perlecan morphants, the lumen of the DA was often collapsed and devoid of
erythrocytes at 4 dpf (Fig. 4 B), although at earlier time points,
the lumen was patent with circulation (see Perlecan is essential
for developmental angiogenesis...). In addition, we observed a
significant disruption of the muscular architecture in the perlecan morphants, with numerous vacuolizations and nucleated
cells indicating muscle regeneration (Fig. 4 B). These lesions
were found throughout the entire myotome, suggesting an essential role for perlecan in muscle development and maintenance. Ultrastructural analysis of various basement membranes,
including vessels, skin, and notochord, showed no significant
alterations in the morphants (Fig. 4, C–I), which is in agreement
with the perlecan-null mice in which basement membrane
assembly is developmentally normal (Arikawa-Hirasawa et al.,
1999; Costell et al., 1999).
Loss of perlecan causes an unexpected
severe myopathy

To understand the effects of perlecan knockdown on muscle patterning, we performed a detailed ultrastructural analysis of the

control and morpholino-treated embryos. The muscular phenotype was evident at 2 dpf with significant loss of myofilaments
and disruption of mitochondria (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200708022/DC1). However, the muscular phenotype became progressively more severe with time.
By 5 dpf, control embryos exhibited a well-defined muscle structure, with highly organized bundles of myofibers surrounded by
mitochondria and glycogen (Fig. 5 A). In contrast, morphants
induced by either translation- or splice-blocking morpholinos
showed a marked disarray of muscle fibers (Fig. 5, B and C).
Often, the filaments appeared to be interwoven, and clear (less
electron dense) bands traversed the sarcomeres at a longitudinal
angle, whereas the I bands, the clear bands containing the thinner
and darker Z bands, were often misaligned and tortuous (Fig. 5 C).
In cross sections, control filaments were assembled in a hexagonal arrangement typical of mature myofibrils, with each thick
filament (myosin filaments) encircled by six thin filaments of
actin that are situated at the trigonal positions of the lattice so
that each is shared by three equidistant thick filaments (Fig. 5,
D and F). In the perlecan morphants, cross section analysis confirmed the misalignment and irregular ultrastructure observed in
the longitudinal sections. Specifically, we found irregular hexagonal arrays and areas in which the thick filaments were not associated with thin filaments (Fig. 5 E). Because of the interwoven
and twisted nature of the sarcomere, it was difficult to take
focused electron micrographs, and, in the few exceptions, the thin
filaments of actin were irregularly aligned with the thick myosin
filaments (Fig. 5 G). Essentially, myofilaments were present but
incorrectly oriented. However, the structure of the sarcoplasmic
reticulum was fully preserved.
Next, we investigated the distribution of actin-containing
filaments using fluorescently labeled phalloidin. The morphants
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Figure 6. Muscular analysis in perlecan morphant embryos. (A and C) Filamentous actin confocal immunohistochemistry. Arows in C highlight clear
spaces between the muscle ﬁbers. (B and D) Corresponding DIC analysis of the trunk musculature from a control and morphant embryo at 5 dpf. (E–J)
Birefringence analyses under polarizing light comparing control and morphant trunk muscle at 2–3 dpf. F, H, and J are magniﬁed views of the boxed regions in E, G, and I, respectively. Arrows in H indicate regions of hypobirefringence. (K–N) Binding of ﬂuorescently labeled ␣-bungarotoxin and fasciculin
to 4-dpf control and morphant embryos as a means to examine the distribution of AChR (red; highlighted by arrowheads in K and N) and AChE (green;
highlighted by arrows in L and M). Bars, 300 μm.

387

Published April 21, 2008

Perlecan is essential for developmental
angiogenesis and cardiovascular function

To monitor vascular development, we used two transgenic zebrafish expressing gfp under the guidance of either the fli1 (Lawson
and Weinstein, 2002) or vegfr2 promoter (Cross et al., 2003).
The transcription factor fli1 and vegfr2/flk1 are two endodermal
388
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vascular markers of vascular cell fate and specification (Carmeliet,
2005). Thus, in both transgenic fish, there is an endothelial-specific
expression of gfp, thereby allowing continuous in vivo observation of vertebrate embryonic vascular development.
In contrast to the axial vessels, DA and PCV, the ISVs and
parachordal vessels develop through angiogenesis (Childs et al.,
2002). The ISVs are the primary sprouts emerging from the DA at
ⵑ1 dpf. They are partially patent by 1.5 dpf and fully functional by
2 dpf (Isogai et al., 2003). The ISVs follow a pattern that is independent from circulation and is tightly regulated by spatially and temporally defined genetic cues (Childs et al., 2002; Isogai et al., 2003).
As the growing ISVs approach the dorsolateral roof of the neural
tube, they divide into two major branches that turn caudally and
rostrally to form the DLAVs (Isogai et al., 2001, 2003). The secondary angiogenic sprouts emerge exclusively from the PCV and develop into the primary vascular network. The parachordal vessels,
which are positioned along the horizontal myoseptae at either side
of the notochord, arise by angiogenic growth of secondary sprouts
from the PCV (Isogai et al., 2003). The perlecan morphants showed
relatively well-developed axial vessels but exhibited significant
suppression of ISVs as compared with control embryos (Fig. 7,
A–D). At 2 dpf, the ISVs were only partially formed, and the
DLAVs were not formed at all in the most severe phenotypes induced by the translation-blocking morpholino MO-DI. The sprouts
exhibited a reduced protrusive activity and were very thin and blunt
ended. The endothelial cells often did not completely migrate along
the myoseptae from the DA (>90%; n = 287 in six separate experiments) and followed abnormal paths failing to interconnect. In most
cases, the ISV stopped at the level of the notochord (Fig. 7,
B and D) and failed to form the regular lattice of vessels present on
either side of the trunk. At later stages, some ISV sprouts reached
the DLAV level, but they did not properly assemble these vessels,
and several misguided vessel branches were noted growing away
from the vertical myoseptae (Fig. S4, available at http://www.jcb
.org/cgi/content/full/jcb.200708022/DC1). The persistence of these
anomalous vessels at 3–4 dpf indicates that the phenotype of the
perlecan morphants is not the result of just a nonspecific developmental delay caused by the morpholino injection. Identical vascular changes were generated by the splice-blocking morpholino
MO-DV (n = 225; six independent experiments; Fig. S5, A–H).
The perlecan morphants induced in the vegfr2-gfp transgenic zebrafish also produced an identical phenotype with a
poorly formed angiogenic network (Fig. S5, I–N). In addition,
there was pericardial edema and stretching of the atrium and ventricle, which became more severe with time (Fig. S5, K–N). Similar
results were obtained with the splicing morpholinos MO-DV
and MO-DIII (unpublished data). Overall, there was a concurrent
reduction in heart beats per minute with a mean of 98 ± 8 for the
morphants versus 158 ± 11 for the controls (n = 24; P < 0.001).
By live DIC videomicroscopy, we observed robust circulation in the control heart, head, and axial vessels as well as the
various branches emanating from the DA, PCV, and DLAV
(Videos 2 and 4, available at http://www.jcb.org/cgi/content/
full/jcb.200708022/DC1). In contrast, in the most severe phenotype caused by the knockdown of perlecan, we observed
no circulation in the head and trunk regions in spite of robust
heart contraction (Video 3). In the milder morphant phenotype,
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exhibited blocky somites, with less defined chevron-shaped
boundaries and often clear spaces between the muscle fibers
(Fig. 6 C, arrows). The muscle bundles were often interwoven,
which is better illustrated under differential interference contrast (DIC) microscopy (Fig. 6 D), as compared with the regular
array of muscle bundles in the control larvae (Fig. 6, A and B).
Examination of control embryos using polarized light
microscopy, a technique used to investigate various muscle mutant zebrafish (Granato et al., 1996; Kunkel et al., 2006), revealed
that axial muscle was highly birefringent at 2 dpf (Fig. 6,
E and F) as a result of the ordered array of myofilaments in striated
muscle. In contrast, perlecan morphants showed an overall decrease in birefringence with patchy areas of hypobirefringence,
suggesting a severe disruption of the sarcomeric structures
(Fig. 6, G and H). Moreover, in the morphants with a moderate
phenotype, the chevron-shaped myoseptae were smooth and
u shaped (Fig. 6, I and J).
Next, we studied the muscular expression of acetylcholine
esterase (AChE) and its receptor (acetylcholine receptor [AChR])
in control and morphant embryos. The rationale for these studies
is based on the fact that a set of molecules, including AChE,
AChR, perlecan, and dystroglycan, cluster at the neuromuscular
junction, where muscle contraction is initiated (Rotundo, 2003).
The collagen-tailed form of AChE is highly expressed in the innervated regions of skeletal muscle fibers and is attached to the
synaptic basement membrane. It has been shown that perlecan
is essential for targeting of the collagen-tailed form of AChE to
the neuromuscular junction (Arikawa-Hirasawa et al., 2002).
We used whole mount zebrafish embryos at 4 dpf and two toxins,
AlexaFluor488-labeled fasciculin (green) and AlexaFluor555labeled ␣-bungarotoxin (red), to label AChE and AChR, respectively. In control zebrafish trunk, AChR was distributed as a fine
array along the fibers and at myoseptal junctions (Fig. 6 K),
whereas AChE labeling was diffuse with focal clustering at the
myoseptal junctions (Fig. 6 L). The perlecan morphants displayed a marked reduction and mislocalization of AChR, and
short clusters of AChE were detected at the myoseptal junctions,
often with skipping of somites (Fig. 6 M). In the most severe
morphants, AChR clustered to intersomitic septae (Fig. 6 N),
with the somites mostly devoid of AChR.
Collectively, our findings indicate that perlecan is essential for the development and integrity of somitic muscle and
suggest a relationship between AChR and perlecan. The lesions
were found throughout the entire myotomes, demonstrating an
essential role for perlecan in skeletal muscle development and
maintenance. The loss and misalignment of myofilaments could
potentially induce abnormal and uncoordinated movement. This
could provide a plausible explanation for twisting of the body
and tail and for the circular swimming observed in the perlecan
morphants with severe phenotypes (Video 1).
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Figure 7. Vascular analysis in Tg(ﬂi1:egfp)y1 perlecan morphant embryos. (A and B) Epiﬂuorescence microscopy with 3D deconvolution comparing the
trunk vasculature of 2-dpf control versus MO-DI embryos. Note the correct formation of DLAV, ISV, DA, and PCV in the control (A). In contrast, the perlecan
morphant (B) exhibits abnormal ISVs. Often the ISV sprouts fail to completely migrate along the myoseptae and to anastomose (arrows). (C and D) Merged
images corresponding to those shown in A and B taken with both ﬂuorescence deconvolution and DIC microscopy. Note that the ISVs barely reach the
notochord (NC) and do not properly migrate to the dorsal region, thereby failing to interconnect and properly form the DLAV. (E and F) Lateral and dorsal
views of alkaline phosphatase–stained control embryos at 3 dpf. Notice the well-developed SIV. (G–I) Three representative MO-DI perlecan morphants
showing the complete absence of SIV and reduced alkaline phosphatase staining throughout the trunk vasculature and head region. Notice that J is a higher
magniﬁcation of G. The only detectable signal is present along the axial vessels (arrows in G and J). Bars, 500 μm.

we saw regular blood flow through the axial vessels but a greatly
diminished or absent circulation in the ISVs and DLAVs
(Videos 5 and 6). These results indicate that the disrupted or
malformed ISVs and DLAVs are not functionally patent in the
perlecan morphants.
Next, we examined endogenous alkaline phosphatase
activity as a marker enzyme for the developing vasculature.
In control embryos, the endogenous alkaline phosphatase activity labeled the major cerebral and axial vessels as well as the
subintestinal vessels (SIVs), which develop by angiogenesis
from the DA at ⵑ3 dpf (Fig. 7, E and F). In contrast, all MO-DI

morphants showed a marked reduction in alkaline phosphatase
staining of the head and axial vessels and a total absence of SIV
labeling (Fig. 7, G–J). The profound effects of perlecan knockdown on endothelial cell alkaline phosphatase activity suggests
that the vascular changes are not secondary to abnormal somitic
muscle development but are specific for endothelial cells, further proving the significant effects of perlecan deficiency on
developmental angiogenesis. We conclude that perlecan is essential for both robust migration of the primary endothelial
sprouts and for maintaining the path of these vessels along the
vertical myoseptae.
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Figure 8. Partial rescue of the perlecan morphants by human perlecan and endorepellin. (A) Coomassie blue–stained 3–8% Tris-borate gradient gel of
human perlecan immunopuriﬁed from human coronary artery endothelial cells (left). Note the large and broad band corresponding to Mr of >500 kD.
The right panel shows a Coomassie blue–stained 10% SDS-PAGE of human endorepellin. (B and C) Composite photographs of control, MO-DI, and MO-DI
coinjected with perlecan or endorepellin at the designated concentrations. The rescue phenotype was calculated based on the degree of body twisting as
compared with the microinjection of MO-DI alone. Notice the partial rescue of the twisted body phenotype in both cases. Bar, 500 μm.

Rescue experiments using human perlecan
and endorepellin

Conclusive determination of any phenotype is generally made
through targeting of the same gene at several nonoverlapping sites
using antisense morpholinos or by RNA/protein rescue. Given the
large size of perlecan mRNA (predicted mRNA of ⵑ12 kb), rescue
of the morphant phenotype by the overexpression of cRNA encoding full-length zebrafish perlecan would be technically impractical.
Because of the high degree of homology between human and zebrafish perlecan, we chose to inject human perlecan or endorepellin.
The former was immunopurified from human coronary artery endothelial cells using an affinity column coupled with antiperlecan
monoclonal antibody (Whitelock et al., 1999), whereas the latter
was purified from the media conditioned by human embryonic kidney 293–Epstein-Barr virus nuclear antigen cells stably expressing
domain V/endorepellin (Mongiat et al., 2003). The purity of the two
390
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preparations is shown in Fig. 8 A. Embryos were injected with
2.5 ng MO-DI and were randomized into two groups. Half of the
embryos received phenol red, whereas the other half received 10 ng
perlecan or domain V/endorepellin. A significant rescue of the
twisted body phenotype (ranging between 66 and 82%; n = 29 for
perlecan and n = 36 for endorepellin) was achieved by coinjection
of full-length perlecan or endorepellin. The rescue of the phenotype
was quite striking, and several zebrafish survived up to larval stage
(Fig. 8, B and C). Notice that the effects of the morpholinos in the
rescued morphants are still visible, including slightly bent tails and
moderate pericardial edema (Fig. 8, B and C), indicating that perlecan and endorepellin were capable of rescuing the phenotype, at
least partially. Collectively, these findings complement the immunohistochemical data, corroborate the specificity of our antisense
strategy, and support a key role for perlecan and endorepellin in
maintaining cardiovascular and musculoskeletal function.
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Discussion
In this study, we used a targeted protein depletion approach
coupled with protein-based rescue experiments to investigate
the role of perlecan in vertebrate development. Perlecan exhibited novel and unique functions in muscle development and
angiogenesis. Moreover, similar phenotypes were observed in
three distinct genetic backgrounds, including wild type and two
transgenic fish lines. The perlecan morphants showed a severe
myopathy characterized by abnormal orientation and reduced
amounts of actin filaments and disorganized sarcomeres. In the
perlecan morphants, primary ISV sprouts initiated but did not
completely extend and showed reduced protrusive activity.
Essentially, vessels were severely constricted or atretic with reduced or absent functional circulation as clearly documented by
live videomicroscopy. Thus, perlecan plays a central role in the
complex process of angiogenesis by providing guidance for
endothelial cell migration and differentiation as well as branching morphogenesis.

In the mouse, perlecan is essential for localizing AChE to the
neuromuscular junctions (Peng et al., 1998, 1999; ArikawaHirasawa et al., 2002; Rotundo, 2003). As the collagen-tailed
form of AChE binds directly to perlecan and colocalizes with
perlecan and AChR when transplanted onto frozen sections
of muscle, it is likely that perlecan is a major acceptor site for
AChE at the neuromuscular junctions (Arikawa-Hirasawa et al.,
2002). This concept is further strengthened by the fact that
perlecan binds to ␣-dystroglycan and that in the absence of
␣-dystroglycan, neither perlecan nor AChE accumulates at the
neuromuscular junctions (Arikawa-Hirasawa et al., 2002). Moreover, the cell surface–binding LG domains of muscle agrin and
perlecan promote AChR clustering in the presence of laminin-2
(Smirnov et al., 2005). The perlecan morphants displayed a
marked reduction and mislocalization of AChR, and short clusters of AChE were noted at the myoseptal junctions, often with
skipping of somites. In the most severe morphant phenotypes,
AChR clustered in small regions corresponding to intersomitic
septae, with the somites mostly devoid of AChR. We note that
in zebrafish embryos and larvae, AChE is not clustered as
in mammalians and is relatively diffuse in the trunk somites
even though the synaptic currents in larvae appears to be mature
(Drapeau et al., 2001). The lesions were found throughout the
entire myotomes, demonstrating an essential role for perlecan
in skeletal muscle development and maintenance. The severity
and progressive myopathy caused by perlecan deficiency may
be partly caused by the fact that zebrafish embryonic muscle may
not possess the regenerative capacity of mammalian muscle (for
review see Bassett and Currie, 2003).
The loss and misalignment of myofilaments could potentially induce abnormal and uncoordinated movement, a plausible
explanation for twisting of the body and tail and for the circular
swimming. These findings indicate that perlecan is essential for
the development and integrity of somitic muscle and suggest a relationship between AChR and perlecan. Notably, a zebrafish null
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Unexpected role for perlecan in
muscular development

mutation in AChE (ache; Behra et al., 2002) shows a muscular
phenotype similar to that of the perlecan morphants, further
stressing the role of AChE in generation of the myopathy.
The muscular phenotype evoked by blocking perlecan expression is similar to that observed in the sapje mutant, in which
expression of the zebrafish orthologue of the X-linked human
Duchenne muscular dystrophy, dystrophin, is absent (Bassett
et al., 2003). The overall loss of myofilaments and muscle architecture of the sapje mutant is similar to the ultrastructural appearance of the perlecan morphant skeletal muscle (see Fig. 6 C of
Bassett et al., 2003). In the sapje mutants, however, the sarcomeres
often collapse as a result of their detachment from the myoseptae,
a process that leads to enhanced fiber death. We did not detect
any clear muscle detachment in the perlecan morphants, suggesting that other factors are involved in this process.
The absence of dystrophin caused by either a mutation in
exon 4 of the dystrophin gene in sapje mutants (Bassett et al.,
2003) or by antisense morpholino (Guyon et al., 2007) leads
to destabilization of the dystrophin-associated protein complex
analogous to what is observed in mammals. A similar muscular
phenotype was observed by knockdown of other members of the
dystrophin-associated protein complex, including dystroglycan
(Parsons et al., 2002) and ␦-sarcoglycan (Guyon et al., 2005).
Domain V/endorepellin binds with high affinity to ␣-dystroglycan
(Talts et al., 1999), and posttranslational or genetic disruption of
dystroglycan function also disrupts perlecan binding to dystroglycan (Kanagawa et al., 2005). Moreover, perlecan and dystroglycan act at the basal side of the Drosophila follicular epithelium
to maintain epithelial organization (Schneider et al., 2006).
Collectively, these data suggest that perlecan is a component of
a trimolecular complex (laminin–perlecan–dystroglycan) whose
disruption could be involved in the pathogenesis of glycosylationdeficient muscular dystrophy (Kanagawa et al., 2005). Domain V/
endorepellin interacts with nidogen, fibulin-2, and collagens IV
and XVIII in basement membranes (Iozzo, 2005; Knox and
Whitelock, 2006), and interaction of skeletal muscle cells with
collagen IV is mediated by cell surface–associated perlecan
(Villar et al., 1999). Thus, perlecan reduction or absence during
development could lead to abnormal cell matrix interactions.
Our findings indicate that perlecan might be directly involved in muscular dystrophy, and, although perlecan mutations
have been implicated in causing Schwartz-Jampel syndrome
characterized by myotonia and chondrodysplasia (Stum et al.,
2006; Rodgers et al., 2007), a role for perlecan in the pathogenesis of muscular dystrophy has never been hypothesized before.
It will be important to investigate perlecan mutations in humans,
especially in patients lacking any mutation in established
human causative genes.
A key role for perlecan in developmental
angiogenesis and cardiovascular function

Anatomically, vascular development in zebrafish proceeds as
in other vertebrates (Isogai et al., 2001, 2003; Childs et al.,
2002; Lawson and Weinstein, 2002). The major axial vessels
derive from angioblast migration from the lateral plate mesoderm,
whereas secondary vessels form by angiogenesis shortly after coalescence of the angioblasts at the midline. Analogous to
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In conclusion, our findings indicate that perlecan functions as a key regulator of somitic muscle development and angiogenesis. This study provides new insights into the biology of
this important macromolecule and its C-terminal angiostatic
fragment endorepellin and predicts the potential existence of
human genetic diseases yet to be characterized in which truncated forms of perlecan might directly affect skeletal muscle
and vascular development without causing embryonic lethality.

Materials and methods
Zebraﬁsh embryos, perlecan morpholino design, and microinjection
Wild-type, Tg(ﬂi1:egfp)y1 (Lawson and Weinstein, 2002), and Tg(vegfr2:
g-rcfp) (Cross et al., 2003) zebraﬁsh embryos were maintained according to
common practice at ⵑ28°C in embryo medium. Before 24 hpf, embryo
medium was supplemented with phenylthiourea to prevent pigmentation.
All embryos were housed in the zebraﬁsh facility of the Kimmel Cancer Center
(Thomas Jefferson University) and were cared for/used in accordance with
university Institutional Animal Care and Use Committee guidelines. Between
1 and 10 ng of morpholino antisense oligonucleotides or morpholino standard
control oligonucleotide was microinjected into one- to two-cell stage embryos
as described previously (Nasevicius and Ekker, 2000). Morpholinos (Gene
Tools, LLC) were designed to either target the 5⬘ untranslated region/translation
start of zebraﬁsh perlecan (MO-DI) or to target a splice junction within
perlecan’s domain III (MO-DIII) or domain V (MO-DV). Perlecan morpholino
sequences were as follows: DI-MO, AGTCTTTCAACTCGACCTTCATTCC;
DIII-MO, ACGAGTCAACCTGCACAACACACAC; and DV-MO, CATCAAACCTGCAAAAGAAAAATGT. The morpholino standard control oligonucleotide
sequence was CCTCTTACCTCAGTTACAATTTATA. Morpholino off-target
effects were assessed by coknockdown of p53 with a translation-blocking
p53MO, GCGCCATTGCTTTGCAAGAATTG, as previously described (Robu
et al., 2007). Gross morphological assessment/phenotypic observations were
visualized with a stereomicroscope (MZFIII; Leica) or microscope (Axioplan2;
Carl Zeiss, Inc.), which were equipped with a GFP ﬁlter set for vascularspeciﬁc analysis in the transgenic embryos, and photographed with a camera
(Axiocam; Carl Zeiss, Inc.) and AxioVision software version 3.0.6.1 (Carl
Zeiss, Inc.). All embryos were mounted in 3–4% methylcellulose on glass
slides and anesthetized with Tricaine when necessary.
Live imaging and digital microscopy
DIC and 3D deconvolved GFP images were collected on a ﬂuorescent microscope (DM5500 B; Leica) equipped with a camera (DFC340 FX; Leica) and
LAS AF version 1.6.1 (Leica). Live videos with DIC microscopy were captured
on the same platform. All video ﬁles were exported as AVI ﬁles, which were
edited in Vegas Movie Studio version 6.0 (Sony) and rendered in QuickTime
Pro version 7.0 (Microsoft). All embryos were mounted in 3–4% methylcellulose
on glass slides and anesthetized with Tricaine when necessary.
Zebraﬁsh whole mount immunohistochemistry
Zebraﬁsh embryos were ﬁxed in 4% PFA (Thermo Fisher Scientiﬁc) in PBS
overnight at 4°C. Postﬁxation embryos were washed three times over 10 min
in 1× PBST (PBS + 0.1% Tween 20), and chorions were removed. Embryos
were permeabilized by immersion ﬁrst in distilled H2O for 5 min followed by
immersion in ice-cold acetone at ⫺20°C for 7 min and immersion in distilled
H2O for 5 min. Embryos were rehydrated in decreasing methanol/PBST series (5 min each in 75, 50, and 25%) followed by washing twice over 3 min
in PBST. Blocking was performed for a minimum of 4 h by immersing the embryos in a solution of 0.1–0.2% BSA (Sigma-Aldrich) at room temperature.
Embryos were incubated with the primary antibody, rabbit anti–mouse
perlecan, as previously described (Handler et al., 1997) at a 1:250 dilution
in blocking solution overnight at 4°C. Embryos were washed in blocking
solution four times over at least 25–30 min. Embryos were incubated with
the secondary antibody, donkey anti–rabbit HRP (GE Healthcare), at a
1:1,000 dilution in blocking solution for ⵑ4 h at room temperature. Embryos
were washed in blocking solution four times over at least 25–30 min. Antibody
staining was visualized by DAB color development according to the manufacturer’s instructions (Dako). Staining reactions were terminated by substrate
removal and thorough washing in 1× PBST. Antibody staining was performed on groups of two to ﬁve embryos. Embryos incubated with secondary antibody alone served as controls. All embryos were photographed
in PBST on an MZFIII stereomicroscope or Axioplan2 microscope with an
Axiocam camera and AxioVision software version 3.0.6.1.
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perlecan knockdown, suppression of Vegfa by antisense morpholino (Nasevicius et al., 2000) or VEGF receptor blockade by the
small molecule SU5416 (Cross et al., 2003) inhibits ISV formation and causes pericardial edema. These data suggest that
the pathology caused by the knockdown of perlecan or VEGFA
is caused by an aberrant vascular system rather than by nonspecific effects.
Using two transgenic lines of zebrafish expressing gfp
driven by the promoter of fli1, an ETS domain transcription factor specific for cells of the hemangioblastic lineage, or vegfr2/
flk1, the major receptor for VEGF, we showed that perlecan was
not required for endothelial cell differentiation and vasculogenesis. However, perlecan knockdown caused a marked reduction
in circulating blood cells in the most severe phenotypes, suggesting a potential role for perlecan in the establishment of angioblast differentiation and lineage. Perlecan morphants showed
a marked impairment in the ability of vegfr2/fli1-expressing
endothelial cells to migrate along the intersomitic septae and
form arterio-venous channels. The live videomicroscopy analysis clearly showed a wide spectrum of vascular changes ranging
from a reduced to a complete lack of circulatory cells in the ISV,
DLAV, and SIV. Disruption of ISV and SIV by knockdown of
perlecan is particularly interesting because these vessels develop by angiogenic sprouting, a process that closely resembles
tumor angiogenesis. Notably, antisense targeting of perlecan
blocks tumor growth and angiogenesis in vivo (Aviezer et al.,
1997; Sharma et al., 1998).
We do not know whether the abnormal endothelial cell migration and pathfinding is caused by a structural role, abnormal
signaling of molecules involved in angiogenesis, or a combination of both. Ultrastructural analysis of vascular, epithelial, and
notochord basement membranes revealed no significant abnormalities in the perlecan morphants, which is in keeping with the
findings of the perlecan-null mouse (Arikawa-Hirasawa et al.,
1999; Costell et al., 1999). We favor the possibility that part of
the vascular phenotype in the perlecan morphants is caused by
abnormal signaling events mediated by hedgehog (hh) and Vegf
proteins and their receptors (Covassin et al., 2006).
Perlecan regulates signaling via protein–protein and protein–
carbohydrate interactions (Iozzo, 1998), and recent evidence
indicates that perlecan regulates shh signaling during development
(Park et al., 2003) and cancer (Datta et al., 2006a,b; Lindner
et al., 2007). In zebrafish embryos, Hh is secreted by the midline
structures (floor plate, notochord, and hypochord) and is at the
top of the signaling cascade controlling vasculogenesis, which
also includes vegf and notch (Lawson et al., 2001, 2002). Moreover, Hh is not only required for adult blood stem cell formation
and for the expression of artery-specific genes by aortic endothelial cells but is also required for angiogenic sprouting of primary
ISV (Gering and Patient, 2005). Interestingly, Hh is essential
for endothelial chord and tube formation in avian and murine
embryos (Vokes et al., 2004), suggesting that its role in vasculogenesis is conserved in vertebrate embryos. Thus, a plausible
scenario is that during somitogenesis and vasculogenesis, Hh
activity is perturbed by the lack of perlecan, which might also
affect the vegf–vegfr2 axis as well as other potential players
such as the fgf–fgfr signaling pathway.
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Endogenous alkaline phosphatase–based vascular staining
1–3 dpf wild-type embryos were ﬁxed in 4–5% PFA and dehydrated in increasing methanol/PBST series to 100% methanol for storage at ⫺20°C.
Embryos were acetone immersed for 30 min at ⫺20°C followed by washing twice for 5 min each in 1× PBST (0.1% Tween 20). Embryos were
equilibrated in alkaline phosphatase staining solution three times for 15 min
at room temperature (0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, and 0.05 M
MgCl2) and subsequently incubated with the alkaline phosphatase substrates nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate,
4-toluidine salt according to the manufacturer’s instructions (Roche). Staining
reactions were terminated by substrate removal and thorough washing in
1× PBST. Endogenous alkaline phosphatase staining was performed with
three embryos per group. Embryos were imaged in PBST with a stereomicroscope (MZ16FA; Leica) equipped with a camera (DFC500; Leica)
and Application Suite version 2.5.0 R1 (Leica).

Zebraﬁsh endorepellin riboprobe generation and whole mount ISH
For endorepellin/domain V riboprobe generation, zebraﬁsh perlecan domain V sense/antisense riboprobes were synthesized by in vitro transcription from the TOPO (zebraﬁsh domain V) plasmid with Sp6 (Thermo Fisher
Scientiﬁc) or T7 (Promega) RNA polymerase and were digoxigenin labeled
via digoxigenin-UTP (Roche) incorporation during the in vitro transcription
reaction. For ISH, RNA localization/detection with sense/antisense riboprobes was performed on groups of two to ﬁve embryos essentially as described previously (Childs et al., 2002). All embryos were photographed
on an MZFIII stereomicroscope or Axioplan2 microscope with an Axiocam
camera and AxioVision software version 3.0.6.1.
Protein rescue
Human perlecan was immunoafﬁnity puriﬁed from the secretions of human
coronary arterial endothelial cells using an afﬁnity column containing a
monoclonal antibody against perlecan protein core (Whitelock and Iozzo,
2002). Recombinant human endorepellin was puriﬁed from 293-–EpsteinBarr virus nuclear antigen cells stably transfected with the appropriate vector (Mongiat et al., 2003; Bix et al., 2007). The proteins were diluted to
reach a concentration of ⵑ1 μg/l, and 2.5–4 nl were microinjected into
one- to two-cell stage embryos either alone or in combination with antisense morpholino.
Online supplemental material
Table S1, Table S2, and Fig. S1 show structural analysis of zebraﬁsh perlecan and comparative analysis of Danio rerio domain V/endorepellin
(TPA BK006379 and GenBank/EMBL/DDBJ accession no. EU379567).
Fig. S2 shows a comparison of MO-DI and MO-DV perlecan morphants
and p53 coknockdown experiments. Fig. S3 shows abnormal skeletal
muscle structure at 2 dpf in perlecan morphants. Fig. S4 shows protracted perlecan knockdown effects on vascular development. Fig. S5
shows vascular analysis in Tg(ﬂi1:egfp)y1 and Tg(vegfr2:g-rcfp) perlecan morphant embryos. Video 1 shows abnormal swimming of perlecan morphants, and Videos 2–6 show circulatory analysis through
the heart, head, and axial vessels in control and perlecan morphant
embryos. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200708022/DC1.
We thank George Purkins for help with the video editing, Bodil Tuma for electron
microscopy, Richard L. Rotundo for providing valuable probes, Amy Rubinstein
for providing the transgenic vegfr2–g-rcfp zebraﬁsh, Peter Yurchenco for providing the antiperlecan antibody, David Birk for use of the Leica microscope,
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Submitted: 3 August 2007
Accepted: 24 March 2008

References
Arikawa-Hirasawa, E., E. Watanabe, H. Takami, J.R. Hassell, and Y. Yamada.
1999. Perlecan is essential for cartilage and cephalic development. Nat.
Genet. 23:354–358.
Arikawa-Hirasawa, E., S.G. Rossi, R.L. Rotundo, and Y. Yamada. 2002. Absence
of acetylcholinesterase at the neuromuscular junctions of perlecan-null
mice. Nat. Neurosci. 5:119–123.
Aviezer, D., D. Hecht, M. Safran, M. Eisinger, G. David, and A. Yayon. 1994.
Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth
factor-receptor binding, mitogenesis, and angiogenesis. Cell. 79:1005–1013.
Aviezer, D., R.V. Iozzo, D.M. Noonan, and A. Yayon. 1997. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable
expression of perlecan antisense cDNA. Mol. Cell. Biol. 17:1938–1946.
Bassett, D.I., and P.D. Currie. 2003. The zebrafish as a model for muscular dystrophy and congenital myopathy. Hum. Mol. Genet. 12:R265–R270.
Bassett, D.I., R.J. Bryson-Richardson, D.F. Daggett, P. Gautier, D.G. Keenan, and
P.D. Currie. 2003. Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development. 130:5851–5860.
Behra, M., X. Cousin, C. Bertrand, J.-L. Vonesch, D. Biellmann, A. Chatonnet,
and U. Strähle. 2002. Acetylcholinesterase is required for neuronal
and muscular development in the zebrafish embryo. Nat. Neurosci.
5:111–118.
Bishop, J.R., M. Schuksz, and J.D. Esko. 2007. Heparan sulphate proteoglycans
fine-tune mammalian physiology. Nature. 446:1030–1037.
Bix, G., J. Fu, E. Gonzalez, L. Macro, A. Barker, S. Campbell, M.M. Zutter, S.A.
Santoro, J.K. Kim, M. Höök, et al. 2004. Endorepellin causes endothelial
cell disassembly of actin cytoskeleton and focal adhesions through the
␣2␤1 integrin. J. Cell Biol. 166:97–109.
Bix, G., R. Castello, M. Burrows, J.J. Zoeller, M. Weech, R.A. Iozzo, C. Cardi,
M.T. Thakur, C.A. Barker, K.C. Camphausen, and R.V. Iozzo. 2006.
Endorepellin in vivo: targeting the tumor vasculature and retarding cancer
growth and metabolism. J. Natl. Cancer Inst. 98:1634–1646.
Bix, G., R.A. Iozzo, B. Woodall, M. Burrows, A. McQuillan, S. Campbell, G.B.
Fields, and R.V. Iozzo. 2007. Endorepellin, the C-terminal angiostatic
module of perlecan, enhances collagen-platelet responses via the ␣2␤1
integrin receptor. Blood. 109:3745–3748.
Carmeliet, P. 2005. Angiogenesis in life, disease and medicine. Nature.
438:932–936.
Childs, S., J.-N. Chen, D.M. Garrity, and M.C. Fishman. 2002. Patterning of
angiogenesis in the zebrafish embryo. Development. 129:973–982.
Costell, M., E. Gustafsson, A. Aszódi, M. Mörgelin, W. Bloch, E. Hunziker,
K. Addicks, R. Timpl, and R. Fässler. 1999. Perlecan maintains the
integrity of cartilage and some basement membranes. J. Cell Biol.
147:1109–1122.
Costell, M., R. Carmona, E. Gustafsson, M. González-Iriarte, R. Fässler, and
R. Munoz-Chápuli. 2002. Hyperplastic conotruncal endocardial cushions
and transposition of great arteries in perlecan-null mice. Circ. Res.
91:158–164.
Covassin, L.D., J.A. Villefranc, M.C. Kacergis, B.M. Weinstein, and N.D.
Lawson. 2006. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in
zebrafish. Proc. Natl. Acad. Sci. USA. 103:6554–6559.
Cross, L.M., M.A. Cook, S. Lin, J.-N. Chen, and A.L. Rubinstein. 2003.
Rapid analysis of angiogenic drugs in a live fluorescent zebrafish assay.
Arterioscler. Thromb. Vasc. Biol. 23:911–912.
Datta, M.W., A.M. Hernandez, M.J. Schlicht, A.J. Kahler, A.M. DeGueme,
R. Dhir, R.B. Shah, C. Farach-Carson, A. Barrett, and S. Datta. 2006a.
Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer
cell growth via the Sonic Hedgehog pathway. Mol. Cancer. 5:9.
Datta, S., M. Pierce, and M.W. Datta. 2006b. Perlecan signaling: helping
hedgehog stimulate prostate cancer growth. Int. J. Biochem. Cell Biol.
38:1855–1861.
Drapeau, P., R.R. Buss, D.W. Ali, P. Legendre, and R.L. Rotundo. 2001. Limits
to the development of fast neuromuscular transmission in zebrafish.
J. Neurophysiol. 86:2951–2956.

PERLECAN IN MUSCLE AND VASCULAR DEVELOPMENT • ZOELLER ET AL.

Downloaded from www.jcb.org on May 22, 2008

RT-PCR
Zebraﬁsh total RNA (n = 23 embryos per group for morpholino veriﬁcation experiment; n = 40 embryos per group for developmental analysis) was isolated
according to the TRIZOL method (Invitrogen). For reverse transcription, total
RNA was annealed with Oligo(dT) primer (Roche) at 70°C for 5 min followed
by the addition of 5× Moloney murine leukemia virus buffer (Thermo Fisher Scientiﬁc), 10 mM deoxynucleotide triphosphates (Thermo Fisher Scientiﬁc), RNAsin (Promega), Moloney murine leukemia virus reverse transcription (Thermo
Fisher Scientiﬁc), and incubation at 42°C for 1 h. Reverse transcription reactions were heated at 90°C for 10 min followed by incubation at 4°C for 2 min
before usage, or reactions were kept at 4°C for prolonged cDNA storage.
Perlecan domain III PCR reactions contained cDNA, 10× PCR buffer (Thermo
Fisher Scientiﬁc), 10 mM deoxynucleotide triphosphates (Thermo Fisher Scientiﬁc), 10 pmol/l DIIIF primer ‘GCTAGTGGATCTGTCTCG’, and 10 pmol/l
DIIIR primer ‘CTCCTCGCTGAAGTGAGT’ (Invitrogen). PCR reactions were
analyzed on 4% agarose gel electrophoresis.

This work was supported, in part, by National Institutes of Health grants
RO1 CA39481, RO1 CA47282, and RO1 CA120975 (to R.V. Iozzo) and
National Institutes of Health National Research Service Award training grant
T32 AA07463 (to J.J. Z). This work is a part fulﬁllment for a doctoral thesis in
Cell and Developmental Biology for J.J. Zoeller.

393

Published April 21, 2008

394

JCB • VOLUME 181 • NUMBER 2 • 2008

Parsons, M.J., I. Campos, E.M.A. Hirst, and D.L. Stemple. 2002. Removal of
dystroglycan causes severe muscular dystrophy in zebrafish embryos.
Development. 129:3505–3512.
Peng, H.B., A.A. Ali, D.F. Daggett, H. Rauvala, J.R. Hassell, and N.R.
Smalheiser. 1998. The relationship between perlecan and dystroglycan
and its implication in the formation of the neuromuscular junction. Cell
Adhes. Commun. 5:475–489.
Peng, H.B., H. Xie, S.G. Rossi, and R.L. Rotundo. 1999. Acetylcholinesterase
clustering at the neuromuscular junction involves perlecan and dystroglycan. J. Cell Biol. 145:911–921.
Robu, M.E., J.D. Larson, A. Nasevicius, S. Beiraghi, C. Brenner, S.A. Farber,
and S.C. Ekker. 2007. p53 activation by knockdown technologies. PLoS
Genet. 3:e78.
Rodgers, K.D., T. Sasaki, A. Aszodi, and O. Jacenko. 2007. Reduced perlecan in
mice results in chondrodysplasia resembling Schwartz-Jampel syndrome.
Hum. Mol. Genet. 16:515–528.
Rossi, M., H. Morita, R. Sormunen, S. Airenne, M. Kreivi, L. Wang, N. Fukai,
B.R. Olsen, K. Tryggvason, and R. Soininen. 2003. Heparan sulfate
chains of perlecan are indispensable in the lens capsule but not in the
kidney. EMBO J. 22:236–245.
Rotundo, R.L. 2003. Expression and localization of acetylcholinesterase at the
neuromuscular junction. J. Neurocytol. 32:743–766.
Schneider, M., A.A. Khalil, J. Poulton, C. Castillejo-Lopez, D. Egger-Adam,
A. Wodarz, W.-M. Deng, and S. Baumgartner. 2006. Perlecan and dystroglycan act at the basal side of the Drosophila follicular epithelium to
maintain epithelial organization. Development. 133:3805–3815.
Sharma, B., M. Handler, I. Eichstetter, J. Whitelock, M.A. Nugent, and R.V.
Iozzo. 1998. Antisense targeting of perlecan blocks tumor growth and
angiogenesis in vivo. J. Clin. Invest. 102:1599–1608.
Smirnov, S.P., P. Barzaghi, K.K. McKee, M.A. Ruegg, and P.D. Yurchenco.
2005. Conjugation of LG domains of agrins and perlecan to polymerizing laminin-2 promotes acetylcholine receptor clustering. J. Biol. Chem.
280:41449–41457.
Stum, M., C.-S. Davoine, S. Vicart, L. Guillot-Noël, H. Topaloglu, F.J. CarodArtal, H. Kayserili, F. Hentati, L. Merlini, J.A. Urtizberea, et al. 2006.
Spectrum of HSPG2 (perlecan) mutations in patients with schwartzjampel syndrome. Hum. Mutat. 27:1082–1091.
Talts, J.F., Z. Andac, W. Göhring, A. Brancaccio, and R. Timpl. 1999. Binding of
the G domains of laminin ␣1 and ␣2 chains and perlecan to heparin, sulfatides, ␣-dystroglycan and several extracellular matrix proteins. EMBO J.
18:863–870.
Tran, P.-K., K. Tran-Lundmark, R. Soininen, K. Tryggvason, J. Thyberg, and
U. Hedin. 2004. Increased intimal hyperplasia and smooth muscle cell
proliferation in transgenic mice with heparan sulfate-deficient perlecan.
Circ. Res. 94:550–558.
Villar, M.J., J.R. Hassell, and E. Brandan. 1999. Interaction of skeletal muscle
cells with collagen type IV is mediated by perlecan associated with the
cell surface. J. Cell. Biochem. 75:665–674.
Vokes, S.A., T.A. Yatskievych, R.L. Heimark, J. McMahon, A.P. McMahon,
P.B. Antin, and P.A. Krieg. 2004. Hedgehog signaling is essential
for endothelial tube formation during vasculogenesis. Development.
131:4371–4380.
Wang, H., K. Julenius, J. Hryhorenko, and F.K. Hagen. 2007. Systematic analysis of proteoglycan modification sites in Caenorhabditis elegans by scanning mutagenesis. J. Biol. Chem. 282:14586–14597.
Whitelock, J.M., and R.V. Iozzo. 2002. Isolation and purification of proteoglycans.
In Methods in Cell-Matrix Adhesion. J.C. Adams, editor. Academic Press,
San Diego. 53–67.
Whitelock, J.M., and R.V. Iozzo. 2005. Heparan sulfate: a complex polymer
charged with biological activity. Chem. Rev. 105:2745–2764.
Whitelock, J.M., L.D. Graham, J. Melrose, A.D. Murdoch, R.V. Iozzo, and P.A.
Underwood. 1999. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells.
Matrix Biol. 18:163–178.
Woodall, B.P., A. Nyström, R.A. Iozzo, J.A. Eble, S. Niland, T. Krieg, B. Eckes,
A. Pozzi, and R.V. Iozzo. 2008. Integrin ␣2␤1 is the required receptor for
endorepellin angiostatic activity. J. Biol. Chem. 283:2335–2343.
Zhou, Z., J. Wang, R. Cao, H. Morita, R. Soininen, K.M. Chan, B. Liu, Y. Cao,
and K. Tryggvason. 2004. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice.
Cancer Res. 64:4699–4702.
Zoeller, J.J., and R.V. Iozzo. 2008. Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci. 6:7.

Downloaded from www.jcb.org on May 22, 2008

Fuki, I.V., R.V. Iozzo, and K.J. Williams. 2000. Perlecan heparan sulfate
proteoglycan. A novel receptor that mediates a distinct pathway for ligand
catabolism. J. Biol. Chem. 275:25742–25750.
Gering, M., and R. Patient. 2005. Hedgehog signaling is required for adult blood
stem cell formation in zebrafish embryos. Dev. Cell. 8:389–400.
Gonzalez, E.M., C.C. Reed, G. Bix, J. Fu, Y. Zhang, B. Gopalakrishnan, D.S.
Greenspan, and R.V. Iozzo. 2005. BMP-1/Tolloid-like metalloproteases
process endorepellin, the angiostatic C-terminal fragment of perlecan.
J. Biol. Chem. 280:7080–7087.
González-Iriarte, M., R. Carmona, J.M. Pérez-Pomares, D. Macías, M. Costell,
and R. Munoz-Chápuli. 2003. Development of the coronary arteries in
a murine model of transposition of great arteries. J. Mol. Cell. Cardiol.
35:795–802.
Granato, M., F.J.M. van Eeden, U. Schach, T. Trowe, M. Brand, M. FurutaniSeiki, P. Haffter, M. Hammerschmidt, C.-P. Heisenberg, Y.-J. Jiang,
et al. 1996. Genes controlling and mediating locomotion behavior of the
zebrafish embryo and larva. Development. 123:399–413.
Guyon, J.R., A.N. Mosley, S.J. Jun, F. Montanaro, L.S. Steffen, Y. Zhou, V.
Nigro, L.I. Zon, and L.M. Kunkel. 2005. ␦-sarcoglycan is required for
early zebrafish muscle organization. Exp. Cell Res. 304:105–115.
Guyon, J.R., L.S. Steffen, M.H. Howell, T.J. Pusack, C. Lawrence, and L.M.
Kunkel. 2007. Modeling human muscle disease in zebrafish. Biochim.
Biophys. Acta. 1772:205–215.
Handler, M., P.D. Yurchenco, and R.V. Iozzo. 1997. Developmental expression
of perlecan during murine embryogenesis. Dev. Dyn. 210:130–145.
Hassell, J, Y. Yamada, and E. Arikawa-Hirasawa. 2002. Role of perlecan in skeletal
development and diseases. Glycoconj. J. 19:263–267.
Iozzo, R.V. 1998. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 67:609–652.
Iozzo, R.V. 2005. Basement membrane proteoglycans: from cellar to ceiling.
Nat. Rev. Mol. Cell Biol. 6:646–656.
Iozzo, R.V., and J.D. San Antonio. 2001. Heparan sulfate proteoglycans: heavy
hitters in the angiogenesis arena. J. Clin. Invest. 108:349–355.
Isogai, S., M. Horiguchi, and B.M. Weinstein. 2001. The vascular anatomy of the
developing zebrafish: an atlas of embryonic and early larval development.
Dev. Biol. 230:278–301.
Isogai, S., N.D. Lawson, S. Torrealday, M. Horiguchi, and B.M. Weinstein.
2003. Angiogenic network formation in the developing vertebrate trunk.
Development. 130:5281–5290.
Kanagawa, M., D.E. Michele, J.S. Satz, R. Barresi, H. Kusano, T. Sasaki, R.
Timpl, M.D. Henry, and K.P. Campbell. 2005. Disruption of perlecan
binding and matrix assembly by post-translational or genetic disruption
of dystroglycan function. FEBS Lett. 579:4792–4796.
Knox, S.M., and J.M. Whitelock. 2006. Perlecan: how does one molecule do so
many things? Cell. Mol. Life Sci. 63:2435–2445.
Kunkel, L.M., E. Bachrach, R.R. Bennett, J. Guyon, and L. Steffen. 2006.
Diagnosis and cell-based therapy for duchenne muscular dystrophy in
humans, mice, and zebrafish. J. Hum. Genet. 51:397–406.
Lawson, N.D., and B.M. Weinstein. 2002. In vivo imaging of embryonic vascular
development using transgenic zebrafish. Dev. Biol. 248:307–318.
Lawson, N.D., N. Scheer, V.N. Pham, C.-H. Kim, A.B. Chitnis, J.A. CamposOrtega, and B.M. Weinstein. 2001. Notch signaling is required for
arterial-venous differentiation during embryonic vascular development.
Development. 128:3675–3683.
Lawson, N.D., A.M. Vogel, and B.M. Weinstein. 2002. sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during
arterial endothelial differentiation. Dev. Cell. 3:127–136.
Lindner, J.R., P.R. Hillman, A.L. Barrett, M.C. Jackson, T.L. Perry, Y. Park, and
S. Datta. 2007. The Drosophila Perlecan gene trol regulates multiple
signaling pathways in different developmental contexts. BMC Dev. Biol.
7:121.
Mathiak, M., C. Yenisey, D.S. Grant, B. Sharma, and R.V. Iozzo. 1997. A role for
perlecan in the suppression of growth and invasion in fibrosarcoma cells.
Cancer Res. 57:2130–2136.
Mongiat, M., S. Sweeney, J.D. San Antonio, J. Fu, and R.V. Iozzo. 2003.
Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 278:4238–4249.
Nasevicius, A., and S.C. Ekker. 2000. Effective targeted gene ‘knockdown’ in
zebrafish. Nat. Genet. 26:216–220.
Nasevicius, A., J. Larson, and S.C. Ekker. 2000. Distinct requirements
for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast.
17:294–301.
Park, Y., C. Rangel, M.M. Reynolds, M.C. Caldwell, M. Johns, M. Nayak, C.J.R.
Welsh, S. McDermott, and S. Datta. 2003. Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem cell division. Dev.
Biol. 253:247–257.

